← Eichor
Study identifier: NCT06595355 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin

Condition: Diabetic Macular Edema · Macular Edema · Retinal Neovascularization  ·  Sponsor: Isfahan University of Medical Sciences

PhasePhase 2/Phase 3
Planned participants52
Who can joinAll sexes, 40 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this study is to evaluate the effectiveness of adding curcumin oral treatment to bevacizumab intravitreal injection in patients with central macular edema. A blind study and a randomized and controlled clinical trial are conducted on diabetic patients with macular edema. The patients are divided into two intervention groups (bevacizumab + curcumin) and control (bevacizumab + placebo). The evaluation of the central thickness of the macula and the evaluation of the central volume of the macula are the primary goals and the evaluation of the best visual acuity of the patient is the secondary goal.

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (1)

Mohsen PouraziziIsfahan, Isfahan University of Medical Sciences, IranRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06595355